Previous Close | 139.83 |
Open | 140.90 |
Bid | 140.61 x 200 |
Ask | 140.79 x 200 |
Day's Range | 139.39 - 141.69 |
52 Week Range | 89.04 - 148.37 |
Volume | |
Avg. Volume | 908,056 |
Market Cap | 14.161B |
Beta (5Y Monthly) | 0.28 |
PE Ratio (TTM) | 38.13 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Dec 29, 1995 |
1y Target Est | N/A |
Neurocrine Biosciences ( NASDAQ:NBIX ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from...
INGREZZA drives strong sales while new drug approvals and a solid cash position underscore a promising future.
Financial Performance and Market Dynamics: A SWOT Analysis of Neurocrine Biosciences Inc